IT Support Engineer

Suki raises $90 million in Series E funding to expand healthcare AI. By Nileena Sunil October 16, 2026 3 Mins Read Suki has secured $90 million in Series E funding to accelerate its growth and expand its artificial intelligence capabilities. The funding round included new investors Healthier Capital, Crosslink Capital and Hercules Capital, as well as existing backers Venrock, Flare Capital Partners, Hedosophia, Philips Ventures and Zoom Ventures. Suki CEO and founder Punit Soni told Fierce Healthcare that the company plans to invest the new capital in three areas: advancing its AI technology, expanding its commercial organization and scaling its partner ecosystem. "The bigger picture is that healthcare AI is moving beyond documentation," Soni said. "Health systems want AI that can do more than capture a conversation. They want intelligence that can support clinical decisions, improve financial performance, and streamline operations." Soni said the industry "doesn't need another collection of disconnected AI tools." "Health systems are already dealing with too many point solutions that don't talk to each other, creating more complexity instead of less," Soni said. "We believe the answer is a connected, intelligent operating system for healthcare, one that brings AI together across clinical, financial, and operational workflows rather than keeping it confined to individual applications." "The goal isn't to build every capability ourselves. It's to bring together the best of healthcare AI in a way that works seamlessly for clinicians and health systems. Our vision is much bigger than ambient documentation or any single AI application. We're building toward a future where intelligence connects the entire healthcare experience," Soni added. According to company executives, Suki has raised more than $250 million to date. Patient encounters involving its AI tools grew 190% year over year in 2026, the executives said. The company now works with more than 250 health care organizations and over 30 technology partners that integrate its AI into their platforms. "What makes Suki particularly compelling is its dual approach: delivering AI directly to clinicians through its own application, Suki for Clinicians, while also powering AI capabilities within the platforms and technologies healthcare organizations already use," Healthier Capital partner Aman Mahajan said. "Combined with its sophisticated AI, deep clinical integrations, and demonstrated outcomes, this approach gives Suki a unique opportunity to scale intelligence across healthcare. We believe Suki can become the foundational infrastructure for how healthcare operates in the AI era." Suki plans to use the funding to develop AI agents capable of handling tasks such as referrals, prior authorizations and follow-up scheduling, according to a company announcement on LinkedIn. The funding announcement follows the launch of a new Suki for Clinicians feature that allows clinicians to ask complex clinical questions through Wolters Kluwer's UpToDate Expert AI API directly within the app. Nileena Sunil is a Reporter for the American Bazaar. A postgraduate in English Literature from Christ University, Bengaluru, she has previously worked as an instructional designer and a copywriter before switching fields.

Suki raises $90M Series E financing for Healthcare AI. A clinician asking about a patient needs an answer that belongs to that patient. Suki is bringing chart information and clinical evidence into the same conversation, expanding the job of an assistant that earned its place by helping write the encounter down. The Redwood City, California company announced $90M in financing as part of its Series E on October 13, 2026. New investors Healthier Capital, Crosslink Capital and Hercules Capital joined existing institutional backers, supporting a healthcare AI business that sells its own clinician application and supplies AI to other software companies. That combination gives the financing an operating purpose beyond adding another feature to a documentation tool. Suki wants to carry information across clinical, financial and operational work, with distribution through both its own interface and its partners' products. Each route brings different people into the decision about how much work the assistant should do. What Suki's Series E financing supports. The financing includes participation from existing investors Venrock, Flare Capital Partners, Hedosophia, Philips Ventures and Zoom Ventures. Suki did not identify a lead investor, disclose a valuation or break the $90M into equity and debt components. The company says the money will advance its AI technology, integrations, partner ecosystem and commercial organization. Healthier Capital Partner Aman Mahajan will join Suki's board as part of the transaction. Bringing a physician and health-system leader into that conversation adds relevant experience to a company pursuing a larger role in clinical work. The announcement describes a prospective board appointment; it provides no reason to infer how individual investors negotiated the financing. Suki's earlier capital provides some context for the scale of that ambition. Its October 2024 Series D was $70M, and an official January 2025 announcement reported $168M raised to that point after an investment from Zoom Ventures. The current release leaves an updated cumulative total unstated, so the useful comparison is the company's expanding remit, rather than a reconstructed lifetime figure. Why the chart and the evidence belong together. Suki launched Ask on October 8, shortly before the financing announcement. Wolters Kluwer confirms that the feature brings patient-specific information and UpToDate Expert AI content into Suki for Clinicians across Epic, Oracle Health, athenahealth and MEDITECH. A clinician can retrieve details from a chart and access source-grounded clinical knowledge within the same working environment. Those are related but distinct kinds of information. A medication list describes something about a particular person; clinical literature supplies evidence a clinician may need when assessing that person's care. Making both easier to retrieve can remove searching and copying from the working day. The commercial opportunity sits in that connection, where an application can become useful at another moment in the visit. Suki describes Ask as information retrieval and synthesis, with clinicians responsible for reviewing the information and making care decisions. That boundary matters when considering the company's broader agent ambitions. A product can prepare information or work for review while responsibility remains with the professional using it, and the interface needs to make that division understandable in practice. Two businesses share the clinical workflow. Founder and CEO Punit Soni's current leadership team includes CTO Joe Chang and CPO Abhi Pathak. Historical accounts also identify Karthik Rajan and Anshu Sharma as cofounders; neither is presented on the current official roster as an operating executive. Suki's company profile dates its founding to 2017, giving the present product expansion a history longer than the latest agent vocabulary. The company now serves clinicians directly through its application while offering SDKs and APIs to technology partners. The SDK route includes prebuilt user interface components; APIs allow a partner more flexibility over its own interface and workflow. That choice lets a technology company decide how much of the integration and presentation it wants to own. For Suki, the partner route creates a commercial relationship with somebody who has a customer relationship of their own. The partner's product managers have to decide how a generated note, patient summary or staged order fits the product they sell. This makes integration quality part of distribution: the supplier's capability must become useful inside another team's decisions about screens, permissions and user habits. Adoption puts the expansion in perspective. Suki reports that more than 450 healthcare organizations use its clinician application and more than 30 technology partners embed its AI. The company also reports more than 10x growth in partner revenue over 2 years. Those are company-reported measures, but they explain why the embedded route deserves attention alongside the application carrying Suki's name. A more specific deployment account comes from Austin Regional Clinic's July announcement with Suki. The organizations reported an 18.5% reduction in documentation time per encounter and 97% engagement among onboarded clinicians. The figures describe that implementation; they should travel with their customer context rather than become a promise about every deployment. Other healthcare software investments illuminate the neighboring work. DevCuration's coverage of Brellium's clinical-note review expansion and Intake AI's clinical-trial operations follows different parts of the information lifecycle. For a buyer, those distinctions help separate products by the work they perform and the people expected to review their output. More work reaches the approval screen. Suki's clinician product already describes order staging that prepares proposed orders for review and approval. That is a concrete example of the company's movement from recording an encounter toward helping carry out the work around it. The proposed action still arrives at a clinician who must understand what has been prepared. The Series E financing supports the technology and commercial capacity behind that expansion. As Suki and its partners put additional capabilities into familiar healthcare software, product teams will keep deciding how context, evidence and approval meet on the screen a clinician actually uses. The assistant's next useful job begins inside that shared design work. DevCuration Data Healthcare AI funding, last 30 days. DevCuration's funding database tracked 19 Healthcare AI rounds totaling $728M in disclosed capital over the past 30 days. Recent deals DevCuration covered: